Videos

This June 17, 2025 SOCS News Update highlights creating strategic plans with mentors and mentees.

At SLEEP 2025, Kancherla highlights diagnostic dilemmas, treatment gaps, and the need for pediatric criteria when managing obstructive sleep apnea in teens.

At SLEEP 2025, Kancherla emphasized the importance of using pediatric criteria to manage OSA in adolescents, warning that adult standards may overlook key developmental factors.

In this video, the last in a 3-part series, panelists discuss future directions in the field and the importance of multispecialty collaboration.

In this video, part 2 in a 3-part series, panelists discuss clesrovimab's recent approval and gaps in clinician education.

In this video, the first in a 3-part series, panelists discuss recent advancements in RSV management.

This interview at RAD 2025 highlights a session on dose flexibility in adult patients with atopic dermatitis, presented by Tejesh Patel, MD.

The recent Lancet Commission on Obesity has repositioned the former risk factor as a disease, indicating and emphasizing a variety of complications.

In this interview with Milaan Shah, MD, the expert consensus panel reviewing deucravacitinib’s safety and efficacy for psoriasis is discussed.

Potentially the first successful CETP inhibitor, obicetrapib has shown positive trial results in reducing the risk of cardiovascular disease when combined with statins.

In this special episode, cohosts preview the most anticipated data and explore clinical implications in diabetes and obesity.

At SLEEP 2025, Fung discussed how combining a masked taper, CBT-I, and a nightly dose-tracking diary helped older adults achieve long-term benzodiazepine discontinuation.

At SLEEP 2025, Fung shared that masked taper plus CBT-I led to higher benzodiazepine discontinuation and improved sleep in older adults.

In this RAD 2025 interview, Paller highlights her team’s findings on disease and family burden of topic dermatitis in children.

Gulati covers the promises and pitfalls of the healthcare world’s increasing focus on obesity as a disease and the variety of complications to which it gives rise.

At SLEEP 2025, Danny Eckert, PhD, discussed new drug therapies for OSA, including tirzepatide, AD109, potassium channel blockers, and acetazolamide.

Budoff suggests monitoring serum lipoproteins like Lp(a) and ApoB to predict cardiovascular disease risk in patients with no conventional indicators.

A recap of 3 Kidney Compass podcast episodes recorded at ERA 2025, including summaries and preview clips.

HCPLive spoke with Bowles at SLEEP 2025 on the staggered schedule, referred to as 1/3/2/3, and how it impacts firefighters' sleep.

A recap of 5 studies to know from the ERA 2025 Congress, including expert perspectives.

At SLEEP 2025, Colvonen discussed RCT findings that showed VeNS significantly improved PTSD and insomnia symptoms, offering a scalable solution for patients awaiting 1-on-1 care.

This interview with Peter Lio, MD, at RAD 2025 provides several insights into the topic of topical steroid withdrawal versus atopic dermatitis and what the distinction may be.

Martin reviews recent trends in cardiovascular disease and contributing underlying risk factors, describing them as a “call to action” for cardiovascular care.

In this interview at RAD 2025, Peter Lio, MD, highlighted whether precision medicine is a possibility in the near future in the atopic dermatitis management space.

Lopez discusses the evolving understanding of the utility of SGLT2 inhibitors and GLP-1 RAs in heart failure care, including both HFpEF and HFrEF.

Incretin-based therapies for obesity and diabetes may be capable of treating a much wider range of diseases, including Alzheimer’s and Parkinson’s.

This interview at RAD 2025 highlights several notes on dose flexibility in atopic dermatitis, with commentary by presenter Raj Chovatiya, MD, PhD.